Sažetak
Razvoj čvrstih farmaceutskih oblika lekova koji su prikladni za primenu kod pedijatrijske populacije pacijenata, ali koji istovremeno omogućavaju i precizno doziranje lekovite supstance, predstavlja jedan od vodećih izazova u farmaceutskoj tehnologiji. Prikazana studija koristi propranolol-hidrohlorid, kao jedan od najčešće primenjivanih lekova koji zahteva prilagođavanje farmaceutskih oblika za primenu kod dece. Višečestični farmaceutski oblici u vidu kapsula napunjenih praškom ili granulama, kao i mini tablete, su izrađene i ispitane u pogledu variranja mase i ujednačenosti sadržaja lekovite supstance. Dobijeni rezultati su upoređeni sa variranjem mase uzoraka koji se dobijaju deljenjem konvencionalnih registrovanih tableta na polovine i četvrtine. Dobijeni rezultati ukazuju na superiornost višečestičnih farmaceutskih oblika, zbog visokog stepena ujednačenosti mase i sadržaja lekovite supstance. Takođe je pokazano da se, zbog unapređene protočnosti, kapsule lakše pune granulama u odnosu na praškove, kao i da takvi farmaceutski oblici imaju veću ujednačenost mase i sadržaja lekovite supstance. Predstavljeni postupak izrade je jednostavan za izvođenje u uslovima apoteke. Mini tablete sa visokim udelom i ujednačenim sadržajem propranolol-hidrohlorida su uspešno izrađene, i predstavljaju značajnu strategiju koja može da omogući efikasno prilagođavanje doze lekovite supstance.
Ključne reči
Array
Array
Array
Array
Reference
Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J. 2013;15(4):1072-81.
Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: Standards and novel strategies for drug administration in pediatrics. J Clin Pharmacol. 2018;58(S10):S26-S35.
Trofimiuk M, Wasilewska K, Winnicka K. How to modify drug release in paediatric dosage forms? Novel technologies and modern approaches with regard to children’s population. Int J Mol Sci. 2019;20(13):3200.
Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms-challenges and recent developments: A critical review. J Appl Pharm Sci. 2020;10(07):155-66.
European Medicines Agency: EMA/CHMP/QWP/805880/2012 - Guideline on pharmaceutical development of medicines for paediatric use 2013 [Internet] [Cited 2020 April]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinepharmaceutical-development-medicines-paediatric-use_en.pdf.
World Health Organization: QAS/08.257/Rev.3. Geneva, 2011. Annex 5: Development of paediatric medicines: points to consider in formulation [Internet] [Cited 2020 April]. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex5TRS970.pdf?ua=1.
European Medicines Agency: EMEA/CHMP/PEG/194810/2005 - Reflection paper: Formulations of choice for the paediatric population 2006 [Internet] [Cited 2020 April]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf.
European Medicines Agency: EMA/761434/2010 - Report on the survey of all paediatric uses of medicinal products in Europe: Executive summary 2011 [Internet] [Cited 2020 April]. Available from:https://www.ema.europa.eu/en/documents/other/report-survey-all-paediatric-usesmedicinal-products-europe-executive-summary_en.pdf.
Medicines.org.uk. 2020. Propranolol tablets 10 mg BP - Summary of Product Characteristics (SPC) - (Emc) [Internet] [Cited 2020 May 24]. Available from:
https://www.medicines.org.uk/emc/product/5888/smpc.
Alims.gov.rs 2020. Propranolol tablets 40 mg - Summary of Product Characteristics (SPC) - Medicines and Medical Devices Agency of the Republic of Serbia [Internet] [Cited 2020 July 24]. Available from: https://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-01419-17-001.pdf.
European Medicines Agency. Hemangiol 3.75 mg/ml oral solution - Summary of Product Characteristics (SPC). [Internet] [Cited 2020 May 24]. Available from:
https://www.ema.europa.eu/en/documents/product-information/hemangioleparproduct-information_en.pdf
Van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G. Statistical analysis of tablet breakability methods. J Pharm Pharmaceutic Sci. 2002;5(2):190-8.
Van Santen E, Barends DM, Frijlink HW. Breaking of scored tablets: a review. Eur J Pharm Biopharm. 2002;53(2):139-45.
Hill SW, Varker AS, Karlage K, Myrdal PB. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. J Manag Care Pharm. 2009;15(3):253-61.
Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash). 2002;42(2):195-9.
Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study. Int J Pharm. 2016;514(1):296–307.
Lee HS, Lee JJ, Kim MG, Kim KT, Cho CW, Kim DD, Lee JY. Sprinkle formulations - A review of commercially available product. Asian J Pharm Sci. 2020;15(3):292-310.
Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - A novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78(3):462–9.
Thomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutcliffe AG. Minitablets: New modality to deliver medicines to preschool-aged children. Pediatrics. 2009;123(2):235-8.
Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: Unmet needs and novel approaches. Int J Pharm. 2011;404(1–2):1–9.
Iyire A, Mohammed AR. Multiparticulate systems for paediatric drug delivery. In: Rajabi-Siahboomi AR. Multiparticulate Drug Delivery. New York: Springer; 2017; p. 213-36.
Desitin.de/produkte/orfiril-long/ 2020. Orfiril long 150 mg - Patient information leaflets (PIL) [Internet] Desitin Arzneimittel GmbH [Cited 2020 July 26]. Available https://www.desitin.de/wp-content/uploads/2019/08/Orfiril_long_150mg-300mg_GI.pdf.
Desitin.de/produkte/levetiracetam-desitin/ 2020. Levetiracetam DESITIN 250 mg - Patient information leaflets (PIL) [Internet] Desitin Arzneimittel GmbH [Cited 2020 July 26]. Available from: https://www.desitin.de/wpcontent/uploads/2019/09/Levetiracetam_Desitin_GI.pdf.
Enzym Lefax forte kapseln [Internet] [Cited 2020 July 26]. Available from:
https://www.medikamente-per-klick.de/images/ecommerce/02/56/02563871_2008
06_de_o.pdf.
European Pharmacopoeia (Ph. Eur.). 10th ed, Strasbourg: Council of Europe, 2020.
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, Gorodischer R. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol. 2005;6:775–9.
Paul S, Chang SY, Dun J, Sun WJ; Wang K, Tajarobi P, et al. Comparative analyses of flow and compaction properties of diverse mannitol and lactose grades. Int J Pharm. 2018;546(1-2):39-49.
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).